Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1977 3
1978 2
1979 4
1980 3
1981 4
1982 7
1983 8
1984 7
1985 8
1986 9
1987 7
1988 6
1989 6
1990 7
1991 3
1992 13
1993 9
1994 12
1995 7
1996 14
1997 10
1998 18
1999 9
2000 15
2001 9
2002 12
2003 16
2004 14
2005 16
2006 10
2007 6
2008 21
2009 14
2010 14
2011 17
2012 16
2013 20
2014 18
2015 26
2016 37
2017 39
2018 34
2019 23
2020 27
2021 31
2022 32
2023 24
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Decreased circulating antibody level"
Page 1
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Yuen KC, et al. Nat Med. 2020 May;26(5):693-698. doi: 10.1038/s41591-020-0860-1. Epub 2020 May 11. Nat Med. 2020. PMID: 32405063 Free PMC article.
Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade (1), this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral bloo …
Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade (1), this has not been co …
S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury.
Li Y, Chen B, Yang X, Zhang C, Jiao Y, Li P, Liu Y, Li Z, Qiao B, Bond Lau W, Ma XL, Du J. Li Y, et al. Circulation. 2019 Aug 27;140(9):751-764. doi: 10.1161/CIRCULATIONAHA.118.039262. Epub 2019 Jun 21. Circulation. 2019. PMID: 31220942
RESULTS: S100a8/a9 was identified as the most significantly upregulated gene during the early reperfusion stage. Knockout of S100a9 markedly decreased cardiomyocyte death and improved heart function, whereas hematopoietic overexpression of S100a9 exacerbated MI/R injury. . …
RESULTS: S100a8/a9 was identified as the most significantly upregulated gene during the early reperfusion stage. Knockout of S100a9 markedly …
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
Roth EM, Davidson MH. Roth EM, et al. Rev Cardiovasc Med. 2018;19(S1):S31-S46. doi: 10.3909/ricm19S1S0002. Rev Cardiovasc Med. 2018. PMID: 30207556 Free article. Review.
Less LDL receptors result in increased LDL-C in the bloodstream but inhibiting or binding the circulating PCSK9 results in increased LDL receptors with the resultant decrease in serum LDL-C. Two PCSK9 inhibitors are currently approved for use: alirocumab and evolocu …
Less LDL receptors result in increased LDL-C in the bloodstream but inhibiting or binding the circulating PCSK9 results in increased …
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD. Avery RL, et al. Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493. Retina. 2017. PMID: 28106709 Free PMC article. Clinical Trial.
Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF. CONCLUSION: The three anti-VEGF treatments examined in this analysis demo …
Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatm …
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
In the alirocumab group, the incidence of MACE after month 4 decreased monotonically across decreasing achieved apoB strata (4.26 [95% CI, 3.78-4.79], 3.09 [95% CI, 2.69-3.54], and 2.41 [95% CI, 2.11-2.76] events per 100 patient-years in strata 50, >35-<50, an …
In the alirocumab group, the incidence of MACE after month 4 decreased monotonically across decreasing achieved apoB strata (4 …
Reproductive immunology.
Gurka G, Rocklin RE. Gurka G, et al. JAMA. 1987 Nov 27;258(20):2983-7. JAMA. 1987. PMID: 3312681 Review.
This could favor the production of blocking antibodies and/or T-suppressor cells, as opposed to cytotoxic antibody and killer cells. ...The antibody itself, or more likely antigen-antibody complexes, may be important in this regard....
This could favor the production of blocking antibodies and/or T-suppressor cells, as opposed to cytotoxic antibody and killer …
Myasthenia gravis.
Palmer AC. Palmer AC. Vet Clin North Am Small Anim Pract. 1980 Feb;10(1):213-21. doi: 10.1016/s0195-5616(80)50012-4. Vet Clin North Am Small Anim Pract. 1980. PMID: 6996286 Review.
Clinically, there is weakness of the muscles of the limbs, neck, and head, together with dilatation of the esophagus. In some cases, circulating antibody to acetylcholine receptor is present and the amount of receptor in the end-plates is decreased. ...The cl …
Clinically, there is weakness of the muscles of the limbs, neck, and head, together with dilatation of the esophagus. In some cases, circ …
Dyslipidemia in systemic lupus erythematosus.
Szabó MZ, Szodoray P, Kiss E. Szabó MZ, et al. Immunol Res. 2017 Apr;65(2):543-550. doi: 10.1007/s12026-016-8892-9. Immunol Res. 2017. PMID: 28168401 Review.
Multiple pathogenetic mechanism is included, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can suppress HDL and increase TG, auto-antibodies can cause the injury of the endothelium, lipoprotein lipase (LPL) activity can be reduced by circulating …
Multiple pathogenetic mechanism is included, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can suppress HDL and increase …
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, Venhaus R, Reyes ML, Durham NM, Creasy T, Huang RY, Kaley T, Reardon DA. Nayak L, et al. Clin Cancer Res. 2022 Jun 13;28(12):2567-2578. doi: 10.1158/1078-0432.CCR-21-4064. Clin Cancer Res. 2022. PMID: 35395080 Free PMC article. Clinical Trial.
Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational burden (TMB); and tumor immune activation signature (IAS). ...CONCLUSIONS: Patients with recurrent glioblastoma have markedly lower baseline …
Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational …
Circulating C1q levels in health and disease, more than just a biomarker.
van de Bovenkamp FS, Dijkstra DJ, van Kooten C, Gelderman KA, Trouw LA. van de Bovenkamp FS, et al. Mol Immunol. 2021 Dec;140:206-216. doi: 10.1016/j.molimm.2021.10.010. Epub 2021 Nov 2. Mol Immunol. 2021. PMID: 34735869 Free article. Review.
Decreased C1q levels are present in several autoimmune conditions. The decreased levels reflect the consumption of C1q by complement activation and serves as a biomarker for disease activity. ...
Decreased C1q levels are present in several autoimmune conditions. The decreased levels reflect the consumption …
625 results